Fennec Pharmaceuticals Inc.
$9.98
-8.4%Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -22.6).
Valuation inputs: P/E -22.6, earnings yield N/A, momentum -8.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -27.8%, ROIC -10.7%).
Profitability stack: net margin -21.8%, ROE -27.8%, ROIC -10.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +50.0%, momentum -8.4%, net margin -21.8%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Fennec Pharmaceuticals Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Fennec Pharmaceuticals Inc. Fair Value Envelope
Fennec Pharmaceuticals Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Fennec Pharmaceuticals Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Fennec Pharmaceuticals Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Fennec Pharmaceuticals Inc. Street Expectations Map
Wall Street analysts project that FENC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 16.00 to a high of 18.00.
The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 16.00 to a high of 18.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Fennec Pharmaceuticals Inc. Insider Positioning
During the last 12 months, insiders have purchased $100K and sold $13.72M worth of FENC shares, resulting in $13.62M of net selling activity.
3 Months
0
0.00
39.8K
291.34K
-291K
-$291K
3-6 Months
0
0.00
1.0M
7.74M
-7.7M
-$7.74M
6-9 Months
4.6K
11.29K
364.2K
3.11M
-3.1M
-$3.10M
9-12 Months
36.2K
88.71K
441.1K
2.58M
-2.5M
-$2.49M
Top Buyers
Raykov Rosty
Director
$100K
Top Sellers
Southpoint Capital Advisors Lp
10 Percent Owner
$10.34M
Hackman Jeffrey S.
Director, Officer: Chief Executive Officer
$2.23M
Raykov Rosty
Director
$1.06M
Rallis Chris A
Director
$85K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $13.62M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
FENC has not reported any dividend yield values in the available annual periods.
fenc Dividend History
Learning Layer
Related Guides
Build conviction on FENC by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.